

## CORRECTION TO “Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model”

In the article referenced above [Fransson MN, Gréen H, Litton J-E, and Friberg LE (2011) *Drug Metab Dispos* **39**:247–255], in Table 3, the RSE value for  $\text{IIV}_{f_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}}$  and the Parameter  $\text{IIV}_{f_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}}$  are incorrect. The corrected table appears below.

The online version has been corrected in departure from the print version.

The printer regrets this error and apologizes for any inconvenience or confusion it may have caused.

TABLE 3  
*Parameter estimates for the final model without covariate relations*

Parameter	Estimate	RSE	LLP 95% CI		RSE/RSE Prior
			Lower	Upper	
		%			
$\text{CL}_{\text{pac}}$ (l/h)	378	8.4	322	441	0.66
$V_1$ (liters)	188	11			0.54
$V_2$ (liters)	1100	8.2			0.68
$V_3$ (liters)	222	14			0.45
$Q_2$ (l/h)	123	10			0.57
$Q_3$ (l/h)	181	13			0.84
$B_{\text{lin}}$	7.89	10			0.91
$B_{\text{CrEL}}$	3.62	9.1			0.81
$B_{\text{max}}$ ( $\mu\text{mol/l}$ )	0.0207	22			0.83
$K_m$ ( $\mu\text{mol/l}$ )	0.0000123	36			
$\varepsilon_{1,\text{pac}}$ (%)	24.4	4.7	22.3	26.8	
$\text{IIV}_{\text{CL}_{\text{pac}}}$ (CV %) <sup>a</sup>	15.3	39 <sup>b</sup>	10.0	22.3	
$\text{IIV}_{B_{\text{lin}}}$ (CV %) <sup>a</sup>	101	34 <sup>b</sup>	67.3	176	
$\text{CL}_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}$ (l/h)	2830	26	1850	4750	
$V_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}$ (liters)	1390	24	945	2230	
$B_{\text{CrEL}, 6\alpha\text{OH}}$	43.0	40	24.4	99	
$B_{\text{nsp}, 6\alpha\text{OH}}$ ( $\mu\text{mol/l}$ )	0.000754	12	0.000588	0.000947	
$\varepsilon_{1, 6\alpha\text{OH}}$ (%)	25.4	5.6	22.9	28.4	
$\varepsilon_{2, 6\alpha\text{OH}, i=1}$ ( $\mu\text{mol/l}$ )	0.00447	30	0.00250	0.00772	
$\text{IIV}_{\text{CL}_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}}$ (CV %) <sup>a</sup>	36.6	36 <sup>b</sup>	25.1	53.8	
$\text{CL}_{\text{p3OH}}/\text{fm}_{\text{pac}}$ (l/h)	1470	16	1090	2020	
$V_{\text{p3OH}}/\text{fm}_{\text{pac}}$ (l/h)	1140	13	883	1490	
$B_{\text{CrEL}, \text{p3OH}}$	8.60	32	5.24	16.1	
$B_{\text{nsp}, \text{p3OH}}$ ( $\mu\text{mol/l}$ )	0.00124	10	0.00103	0.00149	
$\varepsilon_{1, \text{p3OH}}$ (%)	37.7	4.8	34.5	41.6	
$\text{IIV}_{\text{fp3OH}/\text{fm}_{\text{pac}}}$	0.425 <sup>c</sup>	29 <sup>b</sup>	0.245 <sup>c</sup>	0.769 <sup>c</sup>	
$\text{CrEL}_{50}$ (ml/l)	4.48	18	3.55	6.21	
$\text{Hill}_{\text{CrEL}}$	2.71	13	2.20	3.39	
$\text{IIV}_{\text{Hill}_{\text{CrEL}}}$ (CV %) <sup>a</sup>	40.1	38 <sup>b</sup>	26.8	58.9	
$\text{CL}_{\text{diOH}}/\text{fm}_{\text{met}}$ (l/h)	831	15	606	1140	
$V_{\text{diOH}}/\text{fm}_{\text{met}}$ (liters)	167	23	97.1	246	
$\varepsilon_{1, \text{diOH}}$ (%)	49.8	8.4	42.6	59.3	
$\varepsilon_{2, \text{diOH}}$ ( $\mu\text{mol/l}$ )	0.00197	22	0.00134	0.00315	
$\text{IIV}_{\text{CL}_{\text{diOH}}/\text{fm}_{\text{met}}}$ (CV %) <sup>a</sup>	60.7	39 <sup>b</sup>	40.8	104	

$\text{CL}_{\text{pac}}$ , clearance of unbound concentrations of paclitaxel;  $V_1$ ,  $V_2$ , and  $V_3$ , volumes of the central, first, and second peripheral compartment for unbound concentrations of paclitaxel;  $Q_2$  and  $Q_3$ , intercompartmental clearances between the central and peripheral compartments for unbound concentrations of paclitaxel;  $B_{\text{lin}}$ , linear binding to plasma components;  $B_{\text{CrEL}}$ , binding directly proportional to CrEL concentration;  $B_{\text{max}}$ , maximal binding to plasma components;  $K_m$ , concentration at half of the maximal binding to plasma components;  $\text{CL}_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}$  and  $\text{CL}_{\text{p3OH}}/\text{fm}_{\text{pac}}$ , clearance of unbound concentrations of  $6\alpha\text{OH}$ -pac and  $\text{p3OH}$ -pac over fraction metabolized unbound paclitaxel;  $V_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}$  and  $V_{\text{p3OH}}/\text{fm}_{\text{pac}}$ , volume of distribution of unbound concentrations of  $6\alpha\text{OH}$ -pac and  $\text{p3OH}$ -pac over fraction metabolized unbound paclitaxel;  $B_{\text{CrEL}, 6\alpha\text{OH}}$  and  $B_{\text{CrEL}, \text{p3OH}}$ , maximal binding rate to CrEL of  $6\alpha\text{OH}$ -pac and  $\text{p3OH}$ -pac;  $B_{\text{nsp}, 6\alpha\text{OH}}$  and  $B_{\text{nsp}, \text{p3OH}}$ , nonspecific CrEL component for  $6\alpha\text{OH}$ -pac and  $\text{p3OH}$ -pac;  $\text{CrEL}_{50}$ , CrEL concentration at half-maximal binding rate;  $\text{Hill}_{\text{CrEL}}$ , Hill coefficient for CrEL concentration;  $\text{CL}_{\text{diOH}}/\text{fm}_{\text{met}}$ , clearance of unbound concentrations of diOH-pac over fraction metabolized unbound primary metabolite;  $V_{\text{diOH}}/\text{fm}_{\text{met}}$ , volume of distribution of unbound concentrations of diOH-pac over fraction metabolized unbound primary metabolite;  $\varepsilon_1$ , proportional residual error for total concentrations;  $\varepsilon_{2, 6\alpha\text{OH}, i=1}$ , additive error for first sample for each individual of total concentration of  $6\alpha\text{OH}$ -pac;  $\varepsilon_{1, \text{diOH}}$ , additive error for total concentration of diOH-pac;  $\text{IIV}_{\text{CL}_{\text{pac}}}$ ,  $\text{IIV}_{B_{\text{lin}}}$ ,  $\text{IIV}_{\text{CL}_{6\alpha\text{OH}}/\text{fm}_{\text{pac}}}$ ,  $\text{IIV}_{\text{CL}_{\text{p3OH}}/\text{fm}_{\text{pac}}}$ ,  $\text{IIV}_{\text{Hill}_{\text{CrEL}}}$ ,  $\text{IIV}_{\text{CL}_{\text{diOH}}/\text{fm}_{\text{met}}}$ , interindividual variability in the designated parameter.

<sup>a</sup> Coefficient of variation, calculated as  $[\exp(\omega^2) - 1]^{0.5}$ .

<sup>b</sup> With respect to the variance term,  $\omega^2$ .

<sup>c</sup> Estimate given for the corresponding variance term,  $\omega^2$ , of  $\beta$  in eqs. 5 and 6.